Welcome to our dedicated page for Air Industries SEC filings (Ticker: AIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking an aerospace supplier means scanning every contract update, backlog shift, and Form 4 trade. When Air Industries Group discloses a new carrier-based arresting-gear order or a quality-control remediation in an 8-K, investors need it fast. This SEC filings hub brings all Air Industries Group insider trading Form 4 transactions, 10-K narratives, and 10-Q financials into one searchable view.
Instead of wading through 200 pages, let Stock Titan’s AI translate the technical language behind flight-critical landing-gear programs. Our engine surfaces revenue concentration risks, summarizes segment margins, and alerts you to Air Industries Group Form 4 insider transactions real-time. Wondering how contract wins flow into earnings? The platform links each Air Industries Group quarterly earnings report 10-Q filing to backlog tables and cash-flow swings, while plain-English callouts explain inventory builds and defense budget timing.
Use cases include:
- Spotting executive stock moves with Air Industries Group executive stock transactions Form 4
- Reviewing pension funding and warranty reserves via the Air Industries Group annual report 10-K simplified
- Receiving push alerts when an Air Industries Group 8-K material events explained document posts
- Comparing board pay in the Air Industries Group proxy statement executive compensation section
Stoke Therapeutics, Inc. (Nasdaq: STOK) filed a Form 8-K on July 10, 2025 under Item 7.01 (Regulation FD). The filing states that the company issued a press release (Exhibit 99.1) announcing the presentation of data from an analysis that informed the design of the planned Phase 3 EMPEROR study and evaluated the potential effects of the proposed zorevunersen dosing regimen. No financial metrics, study results, or timelines were included in the 8-K. The information is furnished (not filed) and therefore is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically stated.
On July 9, 2025, Sachem Capital Corp. (NYSE American: SACH) filed an 8-K reporting the voting results of its 2025 Annual Meeting of Shareholders.
- Board elections: All five incumbent directors were re-elected; for example, CEO John L. Villano received 14.28 M FOR versus 5.56 M WITHHELD, a support level of roughly 72% of votes cast (13.33 M broker non-votes).
- Auditor ratification: Baker Tilly US, LLP was reappointed with 31.70 M FOR, 0.99 M AGAINST, 0.48 M ABSTAIN—over 96% approval.
- Say-on-Pay: The advisory compensation resolution passed with 11.50 M FOR, 7.39 M AGAINST, 0.95 M ABSTAIN (�58% support), indicating notable shareholder dissent.
- 2025 Omnibus Incentive Plan: Approved with 11.71 M FOR, 6.16 M AGAINST, 1.96 M ABSTAIN (�59% support), giving the company flexibility to grant new equity-based awards.
No earnings updates, financial statements, or transactional disclosures accompanied the filing. While the passage of all items preserves governance continuity and provides new incentive tools, the relatively slim margins on compensation matters suggest investors are monitoring pay-for-performance alignment.